Senior management

Gunilla Osswald
Gunilla Osswald
CEO

Born: 1961

Employed since: 2013

Other assignments: Board member of Egetis Therapeutics AB and SpineMedical AB.

Education: Pharmacist; Ph.D. in biopharmacy and pharmacokinetics at Uppsala University, Sweden.

Experience and prior assignments: More than 30 years of experience in drug development. Executive positions at Astra/ AstraZeneca, including Vice President responsible for the product portfolio in neurodegenerative diseases. Board member of SP Process Development AB, SpineMedical Sverige AB and LPB Sweden Holding AB

Member of BioArctic’s senior management since: 2013

Total holdings* and warrants in BioArctic: 75,070 Class B shares.
Warrants granting acquisition rights to 150,000 Class B shares (2019/2028 program).

Gunilla Andersson
Gunilla Andersson
Senior Director HR

Born: 1961

Employed since: 2019 (contracted since 2014)

Other assignments: Manages her own consulting company focusing on HR.

Education: B.Sc. Human Resource Development and Labor Relations with a specialization in labor rights from Lund University, Sweden.

Experience and prior assignments: 30 years of experience as HR consultant and HR manager in educational organizations and pharma companies such as Pharmacia and Novartis.

Member of BioArctic’s senior management since: 2019

Total holdings* and warrants in BioArctic: 0 shares.
Warrants granting acquisition rights to 20,000 Class B shares (2019/2028 program)

Oskar Bosson
Oskar Bosson
Vice President Investor Relations & Communications

Born: 1976

Employed since: 2020

Other assignments:

Education: M.Sc. Molecular Biotechnology and B.A. in Business Administration from Uppsala University

Experience and prior assignments: 17 years of experience from the communication field globally. Held senior positions in companies such as Sobi, Ovako and most recently Elekta.

Member of BioArctic’s senior management since: 2020

Total holdings* and warrants in BioArctic:4,793 Class B shares.
Warrants granting acquisition rights to 20,000 Class B shares (2019/2028 program)

Johanna Fälting
Johanna Fälting
Vice President Head of Research

Born: 1972

Employed since: 2012

Other assignments:

Education: Ph.D. in Physiology, Stockholm University; Licentiate degree in physiology, Stockholm University; Master’s degree in biology, Stock-holm University, Sweden.

Experience and prior assignments: 19 years of experience in neuroscience/ pharmacology, drug research, translational science and development in the global pharma and biotech industry.

Member of BioArctic’s senior management since: 2012

Total holdings* and warrants in BioArctic: 38,355 Class B shares.
Warrants granting acquisition rights to 20,000 Class B shares (2019/2028 program)

Anna-Kaija Grönblad
Anna-Kaija Grönblad
Chief Commercial Officer

Born: 1968

Employed since: 2021 (contracted since 2020)

Other assignments:

Education: B.A. in Business Administration from Uppsala University, Sweden.

Experience and prior assignments: 25 years of experience from the pharmaceutical industry and private healthcare. Over the years, she has worked in various commercial roles in Sweden and the Nordic and Baltic countries, and in a number of therapy areas with a focus on market access, launch preparations and organizational development. She most recently came from the role as CEO of Sanofi AB, where she was also General Manager Nordic & Baltic countries for General Medicine.

Member of BioArctic’s senior management since: 2021

Total holdings* and warrants in BioArctic: 4,500 Class B shares, privately and through Saimi AB. Warrants granting acquisition rights to 20,000 Class B shares (2019/2028 program)

Lars Lannfelt
Lars Lannfelt
Senior Vice President University Collaborations. Founder of BioArctic in 2003.

Born: 1949

Employed since: 2016

Other assignments: Board member of Demban AB and LPB Sweden AB.

Education: Medical degree (specialist in psychiatry) and doctoral thesis at Karolinska Institutet, Stockholm, Sweden; Associate Professor of Neurogenetics at Karolinska Institutet, specialist in geriatrics.

Experience and prior assignments: More than 35 years of experience in research into Alzheimer’s disease and other neurodegenerative diseases. Professor of Geriatrics at Uppsala University; Senior Professor at Uppsala University and member of the Royal Swedish Academy of Sciences. Founder of BioArctic in 2003, Chairman of the Board and a number of assignments and roles in the company.

Member of BioArctic’s senior management since: 2003

Total holdings* and warrants in BioArctic:
8,639,998 Class A shares through Demban AB.
20,885,052 Class B shares through Demban AB.
0 warrants

Jan Mattsson
Jan Mattsson
Vice President Finance, Chief Financial Officer

Born: 1960

Employed at the company since: 2017.

Other assignments – Experience and prior assignments: More than 30 years of experience in business and administration, including CFO at Sefina Finance AB, Allenex AB, Argnor Wireless Ventures AB, Logitall AB and Investment AB Kinnevik. Board member of Sefina Svensk Pantbelaning AB and Humidus AB.

Education: MBA from Örebro University.

Member of BioArctic’s senior management since: 2017

Total holdings* and warrants in BioArctic: 46,270 Class B shares, privately and through Almsäter Interim Management AB.
Warrants granting acquisition rights to 20,000 Class B shares (2019/2028 program

Mikael Moge
Mikael Moge
Vice President Chemistry, Manufacturing & Control

Born: 1967

Employed since: 2012

Other assignments – Experience and prior assignments: 23 years of experience in drug development and 19 years of experience as R&D director in process development and GMP manufacturing. Former section manager in Process R&D at AstraZeneca.

Education: Master of Engineering chemical engineering, KTH Royal Institute of Technology; Ph.D. in organic chemistry, KTH; Stockholm, Sweden.

Member of BioArctic’s senior management since: 2012

Total holdings* and warrants in BioArctic: 8,360 Class B shares.
Warrants granting acquisition rights to 20,000 Class B shares (2019/2028 program)

Christer Möller
Christer Möller
Vice President Pre-Clinical Development, Chief Scientific Officer

Born: 1959

Employed at the company since: 2006.

Other assignments – Experience and prior assignments: 21 years of experience in developing protein drugs from idea to clinical trials including leading positions at small biotech/pharma companies such as Zymenex A/S. In addition, comprehensive academic experience in pursuing research projects concerning growth factors and preclinical research in diabetes.

Education: B.Sc. in Biology, Stockholm University, Sweden; Ph.D. in Medical Science, Karolinska Institutet, Stockholm, Sweden.

Member of BioArctic’s senior management since: 2006

Total holdings* and warrants in BioArctic: 43,770 Class B shares.
Warrants granting acquisition rights to 30,000 Class B shares (2019/2028 program)

Tomas Odergren
Tomas Odergren
Chief Medical Officer

Born: 1959

Employed since: 2019 (contracted since 2016)

Other assignment: Senior Clinical Consultant at GKeller Consulting

Education: MD Uppsala University, PhD Karolinska Institute, Neurologist certified by the Swedish Medical Society, Diploma in Pharmaceutical Medicine EUCOR/ECPM.

Experience and prior assignments: More than 20 years’ experience from the pharmaceutical industry in leading positions in clinical development at AstraZeneca and H Lundbeck. Chief Specialist ICR Neurology H Lundbeck A/S (2015-2017)

Member of BioArctic’s senior management since: 2020

Total holdings* and warrants in BioArctic: 6,200 Class B-shares.
Warrants granting acquisition rights to 20,000 Class B shares (2019/2028 program)

*Includes holdings by self, closely associated persons, controlled companies or otherwise controlled.